Drug intelligence / Profile preview

BR25293293

Development stage: Unknown
Lead developer: National Center for Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

**BR25293293** is an autologous **CAR-T cell therapy** being developed by the National Center of Biotechnology for **relapsed or refractory hematological tumors**. The product uses a patient's own T cells engineered to express a chimeric antigen receptor so they can recognize and kill malignant hematologic tumor cells. Based on the provided source material, the specific CAR antigen target has **not been disclosed**. The program is being implemented with the National Scientific Oncology Center and the Scientific and Production Center for Transfusionology in Kazakhstan, and is described as a **Phase 1 hospital-exemption breakthrough therapy medicinal product program** under Ministry of Health Order No. 240.

Other names: CAR-T therapy

Beyond the preview

Go deeper on BR25293293.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR25293293.

Explore the full profile